| Literature DB >> 9526566 |
C Gilon1, M Huenges, B Mathä, G Gellerman, V Hornik, M Afargan, O Amitay, O Ziv, E Feller, A Gamliel, D Shohat, M Wanger, O Arad, H Kessler.
Abstract
Cyclo(PheN2-Tyr-D-Trp-Lys-Val-PheC3)-Thr-NH2 (PTR 3046), a backbone-cyclic somatostatin analogue, was synthesized by solid-phase methodology. The binding characteristics of PTR 3046 to the different somatostatin receptors, expressed in CHO cells, indicate high selectivity to the SSTR5 receptor. PTR 3046 is highly stable against enzymatic degradation as determined in vitro by incubation with rat renal homogenate and human serum. The biological activity of PTR 3046 in vivo was determined in rats. PTR 3046 inhibits bombesin- and caerulein-induced amylase and lipase release from the pancreas without inhibiting growth hormone or glucagon release. The major conformation of PTR 3046 in CD3OH, as determined by NMR, is defined by a type II' beta-turn at D-Trp-Lys and a cis amide bond at Val-PheC3.Entities:
Mesh：
Substances：
Year: 1998 PMID： 9526566 DOI： 10.1021/jm970633x
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446